OUR VIEW · OPINION中文

Moderna: what today's price assumes about its cancer platform

By · AI-assisted, human-reviewed and edited · · 11 sources · Fact-checked · 15 min read (16 min with all details)

Our view

Moderna is a COVID vaccine company with a first cancer success: its individualised mRNA therapy intismeran, given with Merck's Keytruda after surgery, cut the risk of melanoma recurrence or death by 42% against Keytruda alone (two-year recurrence-free survival 82.2% against 70.0%; overall survival still immature). The market values Moderna like a platform, at about 36 times the next four quarters' sales by our calculation. We model that: where the next readouts go well by end-2030, we value the whole company at 10 times its forward sales, a platform-biotech level; where they don't, it gets an ordinary vaccine-company value plus its pipeline at the odds. Our range still sits well below today's price. That is the result of our settings, not a verdict; the next section shows what would have to be true for today's price.

Price, Nov 13 close
$223.37
Hurdle, end-2030
$319
Median value, end-2030
$104
P10–P90 range, end-2030
$43–$160
Simulations beating hurdle
0%
End below today's price
99.8%

Prices: Yahoo Finance, CNBC, Nov 16, 2026 · Company data: 10-Q, Sep 30, 2026 · What these numbers mean

Market data as of the Nov 13, 2026 close ($223.37). The hurdle and the probabilities depend on that price. Values per share at Dec 31, 2030, undiscounted, from 50,000 simulations.

Snapshot at the Nov 16, 2026 close

Enterprise value
$82.7B†
Price/sales
34.5×
EV/sales
32.8×
P/E
n/m
Revenue growth
+13%
Net cash
$4.4B†

Our calculation from the company's filings (latest: 10-Q for the quarter to Sep 30, 2026, filed Nov 6, 2026); not investment advice. Revenue, earnings and cash flow: 12 months to Sep 30, 2026. Price $215.27 (Yahoo Finance, CNBC); 404.6 million shares (common shares on the cover page of the 10-Q filed Nov 6, 2026). n/m = not meaningful (e.g. negative earnings). † Debt excludes an $8M research and development funding liability to Blackstone, which Moderna reports separately.

Earlier versions

VersionPrice usedHorizonMedian valueP10–P90Beat chance
Nov 17, 2026THIS VERSION $223.37 (Nov 13, 2026) end-2030$104$43–$1600%

No earlier versions yet. Each row is frozen as published: when we update this view, the previous numbers stay here.

Version 1.5 · Nov 13, 2026

Editors don’t hold this stock, BioNTech or Merck. They hold Alnylam and Arrowhead, which this article mentions as comparisons. Market data as of the Nov 13, 2026 close ($223.37). Yahoo Finance and CNBC agree. Market value about $90B on 404.6M shares outstanding (Oct 30, Q3 10-Q cover). Our model starts from 430.6M shares, an approximate diluted basis: options and stock units on the treasury method, an estimate. The convertible notes are settled separately, net of their capped calls. Latest filings: the 10-K for 2025 and the Q3 2026 10-Q. Analyst Day was Nov 12.

Labels used below: Fact (filings or market data), Company (management claims), Analyst (named or consensus views), Our view (our own reasoning), Our calculation (arithmetic on the sources named). Each section ends with a confidence level.

Simulation result (value per share at Dec 31, 2030, undiscounted; 50,000 simulations):

  • P10 $43 · P50 $104 · P90 $160 (middle half $64–$136; mean $102).
  • Hurdle $319 (the end-2030 price that earns 9% a year from today): 0% of simulations beat it; 99.8% end below today’s price.
End-2030 value per share (undiscounted) P10 P50 (median) P90 Mean Beat the hurdle Below today’s price
Main: 10× sales where readouts go well $43 $104 $160 $102 0% 99.8%
Scenario: 14× $43 $140 $221 $132 0.1% 90.7%
Scenario: 18× $43 $177 $282 $161 3.3% 68.0%
Reference: no platform multiple $41 $78 $128 $82 0% 99.9%

What would have to be true for today’s price

Our view: these are settings in our model, not forecasts. Each one assumes end-2030 value equal to today’s price, so no gain at all over four years. What could prove each one wrong is listed next to it.

For the end-2030 median to equal the Nov 13 close of $223.37 What it would take Against it
A higher platform multiple About 23× forward 2031 sales, fixed, on the paths where the readouts go well (59% of runs), held to 2030. 25× gives a median of about $244; earning 9% a year needs about 33×. Our calculation from our history files (about 45 companies). The usable comparisons are quarter-ends from 2015 to about Q2 2025: EV over the next four quarters’ actual sales, excluding forecast-filled quarters: no biotech at $2B or more of sales reached 15× at any quarter-end. Runs of 25× or more for a year or longer happened only on tiny sales, such as Alnylam from Q1 2017 to Q1 2019 on $0.07–0.29B. That is above anything observed at comparable sales in our sample. It doesn’t test whether platforms re-rate after positive readouts.
Platform success alone Not reached without the platform multiple. Grouped by how many of the four original intismeran indications succeed by end-2030, the medians are $36, $65, $99, $111 and $119 for none to four. None reaches today’s price. —
Much larger cancer sales An earlier test (before the melanoma bridge, without the platform multiple, at $248.69) needed about five times our draft intismeran peaks to approach the price ($238 at ×5). Not rerun on the current inputs. Research’s melanoma bridge puts Moderna’s share of melanoma at a peak of about $2.6B (see section 2).

Our calculation: at the Nov 13 close the price was about 36 times the next four quarters’ sales. That uses the model’s share count at the first simulated quarter-end (median about 433M), $4.4B of net cash and the model’s $2.57B of next-four-quarter sales, so EV is about $92B. On the basic share count it is about $86B.

By outcome (same runs; our calculation). The first three rows cover all runs:

Paths Share of runs Median P10–P90
Lung Phase 3 positive by end-2030 48% $132 $97–$174
Lung negative, two or more Phase 2 readouts positive 11% $122 $90–$158
Neither: ordinary valuation 41% $59 $32–$91

Separate, overlapping subgroups:

  • Melanoma not approved: 12% of runs, median $41 ($23–$94).
  • Melanoma approved, but the readouts don’t qualify for the platform multiple: 32% of runs, median $64.

Our view in brief

  1. Company: Moderna expects 2026 revenue up 15–25%, to about $2.3B at the midpoint, still almost all COVID vaccines. Fact: it made a profit in Q3 on seasonal international deliveries. It held $8.0B of cash and investments at Sep 30, against $3.6B of debt: $3.0B of 0% convertible notes and a $600M loan.
  2. Fact: intismeran’s melanoma result is the first positive Phase 3 for an individualised neoantigen therapy. Merck shares costs and profits equally, “subject to certain exceptions”.
    • Trials: lung (Phase 3), kidney and bladder (Phase 2) are fully enrolled, with event-driven readouts and no announced dates.
    • Company: Moderna and Merck are preparing regulatory submissions for melanoma; no filing date has been given.
  3. Company: costs go up, not down. Analyst Day put cash costs (excluding stock pay and D&A) at about $4B in 2027 and about $4–4.5B a year through 2030, mainly oncology, and didn’t repeat the 2028 cash-breakeven target. Our view: on our inputs, median net cash is about $3.3B at end-2030, after share sales in 73% of runs. That’s about $2.0B raised averaged across all runs, about $2.7B among the runs that raise. The median share count at end-2030 is about 479M.
  4. Our view: our simulation gives a median end-2030 value of $104 a share against a $319 hurdle and the Nov 13 close of $223.37. The 14× and 18× scenarios give $140 and $177.
  5. Our view: the market is paying for platform success above the levels observed at comparable sales scale in our sample. That may prove right. A first platform in a new class has no good comparable, and our model can’t show it from the evidence it has.
  6. Watch: the melanoma filing; kidney and bladder Phase 2 data (registry completion 2027–28); the lung Phase 3 (event-driven, registry completion June 2030); 2027 guidance with the Q4 results; spending against the $4–4.5B cost outlook.

1. The business in one paragraph

Fact:

  • 2025: 93% of Moderna’s $1.94B revenue was COVID vaccines (Spikevax, mNEXSPIKE); the RSV vaccine (mRESVIA) was $8M.
  • 2026 so far: revenue in the first nine months was $1.85B. Q3 was $1.31B: COVID $1,244M, RSV $29M.
  • Flu and the combination: the flu vaccine mFLUSIVA was approved in the US on Aug 5, 2026, for adults 50 and older. The flu and COVID combination is approved in the EU and Canada.
  • Intismeran autogene (V940, with Merck) is made for each patient from their tumour’s mutations.

Company: broader flu launch planned for the 2027–28 season. Confidence: high.

2. Where growth comes from (3–5 years)

  • Company: 2026 revenue +15–25%, about half from the US and half international. The 2027 framework comes with the Q4 results. Analyst Day described 2027 growth drivers as “primarily from infectious disease products and potential intismeran launch”.
  • Our view, vaccines: the franchise grows about 4–6% a year in our inputs. Flu and the combination add $0.3–1.8B at maturity (P10–P90). The 90% figure is our odds of commercial success, not of approval. The step change has to come from cancer.
  • Our view, intismeran: eventual-approval odds, not approval by 2030. Named sources where they exist, otherwise base rates by stage:
    • Melanoma, adjuvant: 88% (Jefferies’ reported 85%; filing-to-approval base rate 92%). Launch window mid-2027 to late 2028.

      • Peak attributable to Moderna: $1.4B / $2.6B / $4.5B (P10/P50/P90), from research’s bridge. Company: about 22,000 eligible US patients a year (Analyst Day).
      • Our assumptions behind the peak: a net price of $230–437K a course (hypothetical, from reported price assumptions), peak uptake 30–70%, and ex-US sales at 25–68% of US. These are taken to move together (our choice), although the model has no overall-survival event linking them.
      • Booking: 50% of worldwide net sales. That’s an analytical convention, since Merck books all sales and the profit-sharing terms are redacted.
    • Lung (Phase 3): readout positive 48% (oncology Phase 3 base rate), then 92% to approval.

    • Kidney and bladder (Phase 2): readouts positive 40% each, our view, above the 24.6% oncology base rate because melanoma’s mechanism worked. Then 31.75% to approval. That keeps the earlier eventual odds of 12.7%, which were set with the all-disease Phase 2 rate; oncology would give 10.8%.

    • Further named programs:

      • first-line melanoma (Phase 2; 40% readout × 27%);
      • first-line squamous lung (Phase 2; 10.8%);
      • stage I lung (Phase 3; 44%);
      • mRNA-4359, mRNA-2808 and mRNA-4194: 5.3% each at Phase 1-entry odds. That is a conservative choice, especially for mRNA-4359, which management describes as in Phase 2.

      Peaks for all of these are drafts with no named source.

  • Confidence: low.

3. The edge (moat)

  • Fact: INTerpath-001 met recurrence-free survival (HR 0.58) and distant metastasis-free survival. Overall survival was immature and not significant at this analysis. Published in NEJM on Nov 11, 2026 (Long et al.).
  • Company:
    • Marlborough is expected to become the global supply site in 2027, with capacity for “up to tens of thousands of patients per year”.
    • The deck reports a median of 64 days to the first intismeran dose.
  • Our view: manufacturing individual vaccines at scale could become an edge, but no comparative evidence shows one yet.
  • Patents and exclusivity: Merck’s 10-K lists V940’s anticipated US patent expiry as 2036, with extensions possible. As a biologic, it would generally get 12 years of US reference-product exclusivity from first licensure, about 2039–40. That’s the general rule; we haven’t checked it against a label, and it doesn’t establish worldwide protection.
  • COVID vaccines: Moderna competes with Pfizer/BioNTech and others in a shrinking, seasonal market.
  • Confidence: medium.

4. The worst realistic risk

  • The main case: the cancer readouts disappoint and the market stops paying a platform multiple. In our runs, 41% of paths don’t qualify for the platform multiple (median $59). In 32% melanoma is approved but the other readouts fall short (median $64), and in 12% melanoma isn’t approved (median $41).
  • Fact, other risks:
    • the patent appeal: up to $1.3B, payable within 90 days if lost;
    • three CureVac suits, unsized.
  • Our view: spending at $4–4.5B a year while COVID sales shrink would mean share sales. Our model prices issues near today’s price, so cheaper financing after a disappointment is a limitation.
  • Confidence: medium.

5. Financial quality (read the notes)

  • Fact (Q3 10-Q):
    • Cash and investments were $8.0B at Sep 30, after $2.6B of net convertible proceeds and the $950M settlement payment.
    • Debt: $3.0B of 0% convertible notes due 2032 (conversion price $210.58, capped calls to $392.62) and a $600M Ares loan.
    • Nine-month operating cash outflow was $2.7B. Stock pay was $351M and D&A $190M in nine months.
  • Company (Analyst Day):
    • The Ares loan is extended to 2031, with $900M more available to 2029.
    • About $9B of total liquidity at end-2026: cash, investments and undrawn credit.
  • Our view: Q3’s profit is seasonal. On the model’s medians, revenue rises from about $2.7B in 2027 to about $4.9B in 2030, against cash costs of $4–4.5B a year in the company’s outlook. Spending stays above revenue for most of the period.
  • Confidence: high on the facts, medium on the outlook.

6. Valuation today

  • Our calculation: about 36× the next four quarters’ sales on the model’s basis (see the first section).
  • BioNTech, its closest mRNA peer, was at about 2.1× EV/TTM sales in Q3 2026 on our quarterly series. That series uses quarterly-average prices and an estimated fixed share count (BioNTech now reports 247.9M shares). Euro balances are converted at quarter-end rates and TTM revenue at quarterly-average rates. The accounting differs: BioNTech’s revenue includes its share of Pfizer’s gross profit, while Moderna reports gross product sales. The gap between the two was small in 2025 and opened in 2026, before and after the melanoma result.
  • Before the Aug 19 news:
    • The comparables rule: US commercial biotechs with $0.5–10B of TTM revenue, operating margin under 10% and TTM growth of −30% to +30%, on June 30 financials and 30-trading-day average prices from Jul 8 to Aug 18.
    • The ten names: Sarepta, Pacira, Supernus, Acadia, Ultragenyx, BioMarin, Alkermes, Ionis, Corcept and Arrowhead.
    • They traded at a median 3.9× EV/TTM sales. Our calculation: that implies about $33 a share for Moderna (draft diluted basis), against $62.96 on Aug 18, so the market was already paying for hopes before the trial result.
    • Limits: four tickers didn’t resolve in our lookup, and Moderna’s losses were far deeper than any of theirs.
  • Confidence: medium.

What the market added around the news (our calculation; event study):

Aug 18 close Aug 19 Nov 5
Moderna $62.96 $174.38 (+177%) $241.46
Merck $135.17 $152.20 (+13%) $146.94
BioNTech $92.75 $113.12 (+22%) $85.86
  • Equity market value on basic shares: on Aug 19 Moderna gained about $44.5B and Merck about $42.1B. From Aug 18 to Nov 5, Moderna gained about $71.3B and Merck about $29.1B.

  • Enterprise value, sector-adjusted, on an earlier draft diluted share basis: Moderna added about $67–69B using 30-trading-day averages ending Aug 18 and Nov 5 (about 424M and 437M shares). Using the Aug 18 and Nov 5 closes it added about $80–82B (about 425M and 439M shares).

  • Qualifications:

    • Over eleven weeks Moderna also had other news: the $3.0B convertible sale (Sep 1), and the full trial data (Oct 22, −18% that day), plus short covering.
    • The XBI and IBB biotech indices contain Moderna and may themselves have moved on the trial.
    • Subtracting them assumes a one-for-one relationship.
    • Merck also gains through Keytruda, so its move isn’t an independent value of its half of the vaccine.

    These describe the moves; they don’t measure the vaccine’s value.

7. Value at end-2030: the simulation

Method (our view):

  • Good-readout paths: lung Phase 3 positive by Dec 31, 2030, or at least two of the three Phase 2 readouts positive (59% of runs). All four readouts are assumed to resolve before the horizon in our windows.
    • On these paths, equity = 10 × the model’s forward 2031 revenue + net cash. The convertible notes are then settled against that value (with the capped calls) and the result divided by diluted shares.
    • That replaces the separate values of the vaccines and the cancer programs, because the multiple is meant to price them.
    • Model revenue includes the 50%-of-worldwide-sales convention for intismeran, not disclosed booked revenue.
    • Platform peers’ realised forward EV/sales medians (our history files): Alnylam 18×, Insmed 14×, Vertex 9×, Ionis 6×; about 10–11× across the four. Commercial pharma: Gilead, AbbVie and Biogen at about 4×.
  • Other paths: the vaccine franchise at its usual sales multiple (anchor 4.1×, simulated median 3.7×), plus each cancer program valued at maturity and discounted at 9–13%, at its odds.
  • Costs: the company’s cash-cost outlook enters as the estimated shortfall above the model’s own spending path (+$0.3–0.7B in 2027, about +$1.0–1.6B a year in 2028–30), calibrated at the median. It is not another full $4–4.5B.
  • Known limits:
    • The platform multiple doesn’t move with our market factor, so the market-level sensitivity barely changes the result.
    • Readout dates are our windows; the company gives none, and registry completion dates aren’t announcement dates.
    • Peaks beyond melanoma are drafts. The added lung programs may overlap the original lung peak.
    • No loss-of-exclusivity erosion is applied, including to later maturity values.
    • Stock pay is counted both as a cash cost and as dilution.
    • Outcome dependence (correlations between readouts and programs) is our assumption.
    • The melanoma sales ramp approximates research’s five-year path at its midpoint.
Scenario Median Beat hurdle Below today’s price
Main, 10× $104 0% 99.8%
14× $140 0.1% 90.7%
18× $177 3.3% 68.0%
No platform multiple $78 0% 99.9%

Confidence: low. The result rests on the platform multiple and draft peaks, more than any report we publish.

8. Management and governance

  • Fact: CEO Stéphane Bancel is a large holder. Moderna bought back $5.3B of stock in 2021–23 and stopped in 2023. The Merck collaboration (2018 agreement) shares costs and profits equally, “subject to certain exceptions”, with the profit-sharing exhibits redacted.
  • Company: oncology is funded from the balance sheet, and spending would fall if readouts disappoint. No amounts are given.
  • Confidence: medium.

9. Signposts

  • Melanoma filing and approval timing. A filing would tighten our launch window, now mid-2027 to late 2028.
  • Kidney (INTerpath-004) and bladder (INTerpath-005) Phase 2 data. Two positives move a run into the good-readout state.
  • Lung Phase 3 (INTerpath-002), event-driven: the largest single readout.
  • 2027 guidance with the Q4 results: cash costs against about $4B, and revenue.
  • Flu’s first full season (2027–28), and the patent appeal.

Confidence: medium.

10. Open questions

  • What multiple will investors pay for a platform after the first positive readouts? Our main case uses 10×, the peers’ level. The price implies about 23×.
  • How much of intismeran’s economics will Moderna book, and at what price per course? The bridge’s figures are illustrative; the contract terms are redacted.
  • Will 2028–30 spending follow the readouts, as management suggests?

Confidence: low.

Pipeline and catalysts (biotech adaptation)

Program Stage Estimated registry primary completion / next milestone Our model: readout window Eventual odds in our model
Intismeran, adjuvant melanoma Phase 3 positive; preparing regulatory submissions Filing (no date given) (resolved) 88%
Intismeran, adjuvant lung (INTerpath-002) Phase 3 Jun 2030, event-driven mid-2029 to late 2030 48% × 92%
Intismeran, adjuvant kidney (INTerpath-004) Phase 2 Jan 2028 Jan–Aug 2028 40% × 31.75%
Intismeran, bladder (INTerpath-005) Phase 1/2 Apr 2027 Q2–Q4 2027 40% × 31.75%
Intismeran, 1L advanced melanoma (INTerpath-012) Phase 2 Jul 2028 Aug 2028–Feb 2029 40% × 27%
Intismeran, 1L squamous lung Phase 2 Jul 2029 — 10.8%
Intismeran, stage I lung Phase 3 Aug 2034 — 44%
mRNA-4359, mRNA-2808, mRNA-4194 Phase 1/2 2029–32 — 5.3% each
Flu (mFLUSIVA) and combination Approved in specified markets Broader launch 2027–28 — 90% (commercial success)
Propionic acidemia (mRNA-3927) Registrational Readout late 2026 — 50%

Sources

Sources (accessed Nov 12–13, 2026): filings, releases, trial registries and data sources
  • Moderna 10-K for 2025 (Feb 20, 2026); 10-Q for Q3 2026 (Nov 6, 2026); Q3 2026 results release (Nov 6, 2026)
  • Moderna Analyst Day presentation and release (Nov 12, 2026)
  • Moderna 8-Ks: Ares loan facility (Nov 24, 2025), convertible notes (Sep 1, 2026), patent settlement (Mar 5, 2026)
  • Long et al., “Intismeran Autogene plus Pembrolizumab for Resected Stage IIB to IV Melanoma”, NEJM, Nov 11, 2026
  • Merck and Moderna INTerpath-001 releases (Aug 19 and Oct 22, 2026; ESMO 2026)
  • Merck 10-K for 2025 (V940 patent)
  • FDA: reference-product exclusivity for biological products
  • BioNTech Q3 2026 release
  • ClinicalTrials.gov: NCT05933577, NCT06077760, NCT06307431, NCT06305767, NCT06961006, NCT07221474, NCT07513376, NCT05533697, NCT07116616; ISRCTN78380445
  • BIO, Informa Pharma Intelligence and QLS: Clinical Development Success Rates 2011–2020
  • Yahoo Finance and CNBC (prices, Nov 13, 2026); StockAnalysis (consensus)
  • Our history files of company valuations (peer multiples)

About Moderna: Website (external site)Investor relations (external site)SEC filings (external site)Wikipedia (external site)

Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.

Disclosure: one or more of our editors own shares of companies named in this article (ALNY, ARWR) as a long-term investment. For education only, not investment advice. Full disclaimer.

Spot an error or have a question? · Corrections policy